MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.18% | 13.29% | 6.03% | 67.77% | 62.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.18% | 13.29% | 6.03% | 67.77% | 62.22% |
| Cost of Revenue | 76.79% | 55.83% | -23.66% | 28.71% | -18.42% |
| Gross Profit | -18.87% | -27.31% | 324.16% | 340.48% | 3,631.40% |
| SG&A Expenses | 30.95% | -14.24% | -28.19% | 64.98% | -38.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -324.50% | 558.23% | -79.88% | -1,803.70% | 61.60% |
| Total Operating Expenses | 53.06% | 16.74% | -26.41% | 41.60% | -27.86% |
| Operating Income | -130.36% | -31.99% | 68.13% | 11.00% | 123.33% |
| Income Before Tax | 45.18% | 37.00% | 11.98% | -17.31% | 45.63% |
| Income Tax Expenses | -- | -- | -- | -- | -4,461.36% |
| Earnings from Continuing Operations | 39.81% | 36.96% | 11.98% | -17.31% | 50.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.81% | 36.96% | 11.98% | -17.31% | 50.43% |
| EBIT | -130.36% | -31.99% | 68.13% | 11.00% | 123.33% |
| EBITDA | -91.68% | -55.40% | 75.25% | 24.83% | 138.00% |
| EPS Basic | 44.44% | 39.51% | 14.55% | 19.51% | 61.43% |
| Normalized Basic EPS | -111.11% | -15.38% | 70.00% | 35.56% | 122.50% |
| EPS Diluted | 44.44% | 39.51% | 14.55% | 19.51% | 61.43% |
| Normalized Diluted EPS | -111.11% | -15.38% | 70.00% | 35.56% | 122.50% |
| Average Basic Shares Outstanding | 9.01% | 3.15% | 4.26% | 45.81% | 28.08% |
| Average Diluted Shares Outstanding | 9.01% | 3.15% | 4.26% | 45.81% | 28.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |